ClinicalTrials.gov

History of Changes for Study: NCT04575597
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Latest version (submitted November 2, 2021) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 October 2, 2020 None (earliest Version on record)
2 October 27, 2020 Recruitment Status, Study Status and Contacts/Locations
3 November 6, 2020 Study Status and Contacts/Locations
4 November 10, 2020 Contacts/Locations and Study Status
5 November 19, 2020 Contacts/Locations and Study Status
6 November 25, 2020 Contacts/Locations and Study Status
7 December 1, 2020 Study Status and Contacts/Locations
8 December 9, 2020 Study Status and Contacts/Locations
9 December 14, 2020 Study Status and Study Identification
10 December 18, 2020 Contacts/Locations and Study Status
11 December 22, 2020 Outcome Measures, Contacts/Locations, Eligibility, Arms and Interventions and Study Status
12 December 30, 2020 Contacts/Locations and Study Status
13 January 15, 2021 Contacts/Locations and Study Status
14 January 20, 2021 Study Status
15 January 22, 2021 Contacts/Locations and Study Status
16 January 28, 2021 Contacts/Locations and Study Status
17 February 9, 2021 Study Status and Contacts/Locations
18 February 17, 2021 Contacts/Locations and Study Status
19 February 24, 2021 Contacts/Locations and Study Status
20 March 11, 2021 Contacts/Locations and Study Status
21 March 15, 2021 Contacts/Locations and Study Status
22 March 16, 2021 Contacts/Locations and Study Status
23 March 25, 2021 Contacts/Locations and Study Status
24 April 1, 2021 Contacts/Locations and Study Status
25 April 9, 2021 Contacts/Locations and Study Status
26 April 16, 2021 Contacts/Locations and Study Status
27 May 25, 2021 Study Status, Contacts/Locations, Arms and Interventions, Eligibility and Study Design
28 May 28, 2021 Contacts/Locations and Study Status
29 June 2, 2021 Study Status and Contacts/Locations
30 June 10, 2021 Contacts/Locations and Study Status
31 June 17, 2021 Contacts/Locations, Study Status and Study Identification
32 June 23, 2021 Contacts/Locations and Study Status
33 June 30, 2021 Contacts/Locations and Study Status
34 July 7, 2021 Contacts/Locations and Study Status
35 July 14, 2021 Contacts/Locations and Study Status
36 July 21, 2021 Contacts/Locations and Study Status
37 July 28, 2021 Contacts/Locations and Study Status
38 August 4, 2021 Contacts/Locations and Study Status
39 August 11, 2021 Contacts/Locations and Study Status
40 August 17, 2021 Study Status
41 August 25, 2021 Contacts/Locations and Study Status
42 September 2, 2021 Contacts/Locations and Study Status
43 September 10, 2021 Contacts/Locations and Study Status
44 September 15, 2021 Contacts/Locations and Study Status
45 September 22, 2021 Contacts/Locations and Study Status
46 September 30, 2021 Contacts/Locations and Study Status
47 October 8, 2021 Recruitment Status, Study Status and Contacts/Locations
48 November 2, 2021 Study Status
Comparison Format:

Scroll up to access the controls

Study NCT04575597
Submitted Date:  March 25, 2021 (v23)

Open or close this module Study Identification
Unique Protocol ID: 4482-002
Brief Title: Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
Official Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.
Secondary IDs: 2020-003368-24 [EudraCT Number]
MK-4482-002 [Merck]
PHRR201209-003186 [Registry Identifier: PHRR]
Open or close this module Study Status
Record Verification: March 2021
Overall Status: Recruiting
Study Start: October 19, 2020
Primary Completion: June 23, 2021 [Anticipated]
Study Completion: December 26, 2021 [Anticipated]
First Submitted: September 30, 2020
First Submitted that
Met QC Criteria:
October 2, 2020
First Posted: October 5, 2020 [Actual]
Last Update Submitted that
Met QC Criteria:
March 25, 2021
Last Update Posted: March 26, 2021 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Merck Sharp & Dohme Corp.
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Detailed Description:
Open or close this module Conditions
Conditions: Coronavirus Disease (COVID-19)
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2/Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 6
Masking: Double (Participant, Investigator)
Allocation: Randomized
Enrollment: 1450 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Part 1: Molnupiravir 200 mg
200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Other Names:
  • MK-4482
Experimental: Part 1: Molnupiravir 400 mg
400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Other Names:
  • MK-4482
Experimental: Part 1: Molnupiravir 800 mg
800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Other Names:
  • MK-4482
Placebo Comparator: Part 1: Placebo
Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Placebo
Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Experimental: Part 2: Molnupiravir
Molnupiravir (dose to be selected) administered orally every 12 hours for 5 days (10 doses total)
Drug: Molnupiravir
Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Other Names:
  • MK-4482
Placebo Comparator: Part 2: Placebo
Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)
Drug: Placebo
Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Percentage of participants who are hospitalized and/or die
[ Time Frame: Up to 29 days ]

Hospitalization (all cause) is ≥24 hours of acute care in a hospital or similar acute care facility. Death is due to any cause.
2. Percentage of participants with an adverse event (AE)
[ Time Frame: Up to ~7 months ]

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
3. Percentage of participants who discontinued study intervention due to an AE
[ Time Frame: Up to 6 days ]

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Secondary Outcome Measures:
1. Time to sustained resolution or improvement of each targeted COVID-19 sign/symptom
[ Time Frame: Up to 29 days ]

The number of days from randomization to the first day on or before study Day 29 for sustained resolution or improvement of each sign/symptom will be assessed.
2. Time to progression of each targeted COVID-19 sign/symptom
[ Time Frame: Up to 29 days ]

The number of days from randomization to the first day on or before study Day 29 for each targeted self-reported sign/symptom will be assessed.
3. WHO 11-point outcomes score on a scale
[ Time Frame: Up to 29 days ]

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 to 10 with higher score indicating clinical progression.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Has documentation of polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with sample collection ≤7 days prior to the day of randomization. PCR is the preferred method; however with evolving approaches to laboratory confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral ribonucleic acid (RNA) or protein are allowed if authorized for use in the country. Serological tests that detect host antibodies generated in response to recent or prior infection are not allowed.
  • Had initial onset of signs/symptoms attributable to COVID-19 for ≤7 days prior to the day of randomization and at least 1 of the following sign/symptom attributable to COVID-19 on the day of randomization.
  • Has mild or moderate COVID-19. Participants with mild COVID-19 must have at least 1 characteristic or underlying medical condition associated with an increased risk of severe illness from COVID-19.
  • Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: Refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception.
  • Females are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP); or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a WOCBP must have a negative highly sensitive pregnancy test (urine or serum test is required) within 24 hours before the first dose of study intervention.

Exclusion Criteria:

  • Is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization.
  • Is on dialysis or has reduced estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2 by the Modification of Diet in Renal Disease (MDRD) equation.
  • Has any of the following conditions: human immunodeficiency virus (HIV) with a recent viral load >50 copies/mL or cluster of differentiation 4 (CD4) <200 cell/mm^3; chemotherapy required within 6 weeks before randomization; a neutrophilic granulocyte absolute count <500/mm^3; autologous or allogeneic hematopoietic stem cell transplant recipient.
  • Has a history of hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3X upper limit of normal at screening.
  • Has a platelet count <100,000/μL or received a platelet transfusion in the 5 days prior to randomization.
  • Has a history of acute pancreatitis within 3 months prior to randomization or a history of chronic pancreatitis.
  • Is taking or is anticipated to require any prohibited therapies.
  • Is unwilling to abstain from participating in another interventional clinical study through Day 29 with an investigational compound or device, including those for COVID-19 therapeutics.
  • Has a baseline heart rate of < 50 beats per minute at rest
  • Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator.
  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments including but not limited to: participants who are not expected to survive longer than 48 hours after randomization, participants who are expected to require mechanical ventilation within 48 hours after randomization, or participants with a recent history of mechanical ventilation, or participants with conditions that could limit gastrointestinal absorption of capsule contents.
Open or close this module Contacts/Locations
Central Contact Person: Toll Free Number
Telephone: 1-888-577-8839
Email: Trialsites@merck.com
Study Officials: Medical Director
Study Director
Merck Sharp & Dohme Corp.
Locations: United States, Arizona
Phoenix Medical Group ( Site 1822)
[Recruiting]
Peoria, Arizona, United States, 85381
Contact:Contact: Study Coordinator 623-815-9800
United States, California
Ruane Clinical Research Group, Inc. ( Site 2406)
[Recruiting]
Los Angeles, California, United States, 90036
Contact:Contact: Study Coordinator 323-954-0400 x236
Men's Health Foundation ( Site 1820)
[Recruiting]
Los Angeles, California, United States, 90069
Contact:Contact: Study Coordinator 310-550-2271
UC Davis Medical Center ( Site 1833)
[Recruiting]
Sacramento, California, United States, 95817
Contact:Contact: Study Coordinator 916-734-2011
United States, District of Columbia
Emerson Clinical Research Institute ( Site 1828)
[Recruiting]
Washington, District of Columbia, United States, 20011
Contact:Contact: Study Coordinator 202-239-0777
United States, Florida
Midway Immunology and Research Center ( Site 1837)
[Recruiting]
Fort Pierce, Florida, United States, 34982
Contact:Contact: Study Coordinator 772-595-9830
Indago Research & Health Center, Inc ( Site 1809)
[Recruiting]
Hialeah, Florida, United States, 33012
Contact:Contact: Study Coordinator 305-825-6588
Advanced Research For Health Improvement LLC ( Site 1816)
[Recruiting]
Immokalee, Florida, United States, 34142
Contact:Contact: Study Coordinator 239-230-2021
Advanced Research For Health Improvement LLC ( Site 1813)
[Recruiting]
Naples, Florida, United States, 34102
Contact:Contact: Study Coordinator 239-230-2021
Bliss Healthcare Services ( Site 1847)
[Recruiting]
Orlando, Florida, United States, 32806
Contact:Contact: Study Coordinator 407-203-5984
United States, Georgia
Javara Inc. ( Site 1869)
[Recruiting]
Albany, Georgia, United States, 31707
Contact:Contact: Study Coordinator 229-255-2731
IACT Health ( Site 1818)
[Recruiting]
Columbus, Georgia, United States, 31904
Contact:Contact: Study Coordinator 706-321-0495
Javara Inc. ( Site 1868)
[Recruiting]
Fayetteville, Georgia, United States, 30214
Contact:Contact: Study Coordinator 999-999-9999
United States, Illinois
Loretto Hospital ( Site 1886)
[Recruiting]
Chicago, Illinois, United States, 60644
Contact:Contact: Study Coordinator 773-626-4300
United States, Nebraska
University of Nebraska Medical Center ( Site 2414)
[Recruiting]
Omaha, Nebraska, United States, 68198
Contact:Contact: Study Coordinator 402-559-4000
United States, New Mexico
University of New Mexico, Health Sciences Center ( Site 1819)
[Recruiting]
Albuquerque, New Mexico, United States, 87131
Contact:Contact: Study Coordinator 505-272-4661
United States, Texas
Saint Hope Foundation, Inc. ( Site 1830)
[Recruiting]
Bellaire, Texas, United States, 77401
Contact:Contact: Study Coordinator 713-839-7111
The Crofoot Research Center, Inc. ( Site 1812)
[Recruiting]
Houston, Texas, United States, 77098
Contact:Contact: Study Coordinator 713-526-0005
Javara Inc. ( Site 1866)
[Recruiting]
Sugar Land, Texas, United States, 77478
Contact:Contact: Study Coordinator 281-340-9355
United States, Washington
Swedish Medical Center First Hill ( Site 1807)
[Recruiting]
Seattle, Washington, United States, 98104
Contact:Contact: Study Coordinator 206-386-2227
Multicare Health System ( Site 1811)
[Recruiting]
Spokane, Washington, United States, 99204
Contact:Contact: Study Coordinator 509-342-3070
Multicare Health System ( Site 1814)
[Recruiting]
University Place, Washington, United States, 98466
Contact:Contact: Study Coordinator 253-403-7249
Brazil
Instituto de Infectologia Emilio Ribas ( Site 0153)
[Recruiting]
Sao Paulo, Brazil, 01246-900
Contact:Contact: Study Coordinator 5511983957007
Brazil, Distrito Federal
Chronos Pesquisa Clínica ( Site 0155)
[Recruiting]
Brasilia, Distrito Federal, Brazil, 72145-424
Contact:Contact: Study Coordinator +556134917804
Brazil, Minas Gerais
Santa Casa de Misericordia de Belo Horizonte ( Site 0150)
[Recruiting]
Belo Horizonte, Minas Gerais, Brazil, 30150-221
Contact:Contact: Study Coordinator +553138790085
Brazil, Parana
Hospital de Clinicas da Universidade Federal do Parana ( Site 0154)
[Recruiting]
Curitiba, Parana, Brazil, 80060-900
Contact:Contact: Study Coordinator +5541998877638
Brazil, Rio Grande Do Sul
Hospital Tacchini ( Site 0157)
[Recruiting]
Bento Goncalves, Rio Grande Do Sul, Brazil, 95700-000
Contact:Contact: Study Coordinator +555434554333
Canada, Ontario
University Health Network - Toronto General Hospital ( Site 0201)
[Recruiting]
Toronto, Ontario, Canada, M5G 2N2
Contact:Contact: Study Coordinator 4163403871
Chile, Region M. De Santiago
Clinica Universidad de los Andes ( Site 0302)
[Recruiting]
Santiago, Region M. De Santiago, Chile, 2820945
Contact:Contact: Study Coordinator 562 2618 3100
Fundacion Arturo Lopez Perez ( Site 0305)
[Recruiting]
Santiago, Region M. De Santiago, Chile, 7500921
Contact:Contact: Study Coordinator 56976013900
Espacio EME ( Site 0304)
[Recruiting]
Santiago, Region M. De Santiago, Chile, 7770086
Contact:Contact: Study Coordinator +56977743678
Clinica Bicentenario Spa ( Site 0306)
[Recruiting]
Santiago, Region M. De Santiago, Chile, 9160000
Contact:Contact: Study Coordinator +569 8264 6265
Colombia, Antioquia
Hospital Pablo Tobon Uribe ( Site 0405)
[Recruiting]
Medellin, Antioquia, Colombia, 050034
Contact:Contact: Study Coordinator +5744459753
Colombia, Cordoba
Oncomedica S.A. ( Site 0407)
[Recruiting]
Monteria, Cordoba, Colombia, 230002
Contact:Contact: Study Coordinator +5747854344
Colombia, Cundinamarca
Caja de Compensación Familiar CAFAM. Sede Centro de Atención en Salud CAFAM Floresta ( Site 0406)
[Completed]
Bogota, Cundinamarca, Colombia, 111211
Colombia, Santander
Fundacion Cardiovascular de Colombia ( Site 0402)
[Recruiting]
Bucaramanca, Santander, Colombia, 680003
Contact:Contact: Study Coordinator +573002087183
Colombia, Valle Del Cauca
Fundacion Valle del Lili ( Site 0401)
[Recruiting]
Cali, Valle Del Cauca, Colombia, 760032
Contact:Contact: Study Coordinator +5723319090
France
CHU Hopital Saint Antoine ( Site 0505)
[Recruiting]
Paris, France, 75012
Contact:Contact: Study Coordinator +331492833170
Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 0504)
[Recruiting]
Paris, France, 75013
Contact:Contact: Study Coordinator +33142160142
Hopital Bichat Claude Bernard ( Site 0503)
[Recruiting]
Paris, France, 75018
Contact:Contact: Study Coordinator +33140257803
France, Gironde
Groupe Hospitalier Pellegrin ( Site 0511)
[Recruiting]
Bordeaux, Gironde, France, 33000
Contact:Contact: Study Coordinator +33556795679
France, Midi-Pyrenees
C.H.U. de Toulouse Hopital Purpan ( Site 0501)
[Recruiting]
Toulouse, Midi-Pyrenees, France, 31059
Contact:Contact: Study Coordinator +33561777508
France, Nord
Centre Hospitalier de Tourcoing ( Site 0502)
[Recruiting]
Tourcoing, Nord, France, 59208
Contact:Contact: Study Coordinator +33320694619
Germany
ZIBP-Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH ( Site 2301)
[Recruiting]
Berlin, Germany, 10439
Contact:Contact: Study Coordinator +49 304519889415
Germany, Baden-Wurttemberg
Universitaetsklinikum Essen ( Site 2305)
[Recruiting]
Essen, Baden-Wurttemberg, Germany, 45147
Contact:Contact: Study Coordinator +492017233171
Germany, Hessen
Universitaetsklinikum Frankfurt ( Site 2302)
[Recruiting]
Frankfurt a main, Hessen, Germany, 60590
Contact:Contact: Study Coordinator +49 69 6301 6140
Israel
Hadassah Medical Center. Ein Kerem ( Site 2100)
[Recruiting]
Jerusalem, Israel, 9112001
Contact:Contact: Study Coordinator +97226779372
Italy
ASST Fatebenefratelli-Ospedale Sacco ( Site 0601)
[Recruiting]
Milano, Italy, 20157
Contact:Contact: Study Coordinator +390239042452
Mexico, Distrito Federal
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran ( Site 0802)
[Recruiting]
Ciudad de mexico, Distrito Federal, Mexico, 14080
Contact:Contact: Study Coordinator +55554182965
Mexico, Guanajuato
Hospital Regional de Alta Especialidad del Bajio ( Site 0807)
[Recruiting]
Leon, Guanajuato, Mexico, 37660
Contact:Contact: Study Coordinator 524772672000
Philippines, National Capital Region
Lung Center of the Philippines ( Site 0902)
[Recruiting]
Quezon City, National Capital Region, Philippines, 1100
Contact:Contact: Study Coordinator +639178999610
Russian Federation
Strategic Medical System LLC ( Site 1114)
[Recruiting]
Saint-Petersburg, Russian Federation, 192148
Contact:Contact: Study Coordinator +79219536683
Russian Federation, Moskva
Central Scientific Research Institute of Epidemiology ( Site 1104)
[Recruiting]
Moscow, Moskva, Russian Federation, 111123
Contact:Contact: Study Coordinator +74959749646
Central Clinical Hospital with Polyclinic ( Site 1105)
[Recruiting]
Moscow, Moskva, Russian Federation, 121359
Contact:Contact: Study Coordinator +74955300111
Russian Federation, Sankt-Peterburg
Medical Research Institute LLC ( Site 1116)
[Recruiting]
Saint Petersburg, Sankt-Peterburg, Russian Federation, 196084
Contact:Contact: Study Coordinator +7 812 369-24-86
St.Petersburg Outpatient Clinic #109 ( Site 1119)
[Recruiting]
Saint-Petersburg, Sankt-Peterburg, Russian Federation, 192289
Contact:Contact: Study Coordinator 89140791336
Limited liability company "Scientific research center Eco-safety" ( Site 1117)
[Recruiting]
Saint-Petersburg, Sankt-Peterburg, Russian Federation, 196143
Contact:Contact: Study Coordinator +78125005203
Russian Federation, Smolenskaya Oblast
Smolensk State Medical University ( Site 1110)
[Recruiting]
Smolensk, Smolenskaya Oblast, Russian Federation, 214019
Contact:Contact: Study Coordinator +74812450603
South Africa, Free State
IATROS International ( Site 1212)
[Recruiting]
Bloemfontein, Free State, South Africa, 9301
Contact:Contact: Study Coordinator +27514440037
South Africa, Gauteng
Mzansi Ethical Research Centre ( Site 1225)
[Recruiting]
Mpumalanga, Gauteng, South Africa, 1055
Contact:Contact: Study Coordinator +27828027555
Jongaie Research ( Site 1223)
[Recruiting]
Pretoria-West, Gauteng, South Africa, 0183
Contact:Contact: Study Coordinator +27723824021
Wits Baragwanath Clinical Trial Site ( Site 1214)
[Recruiting]
Soweto, Gauteng, South Africa, 2013
Contact:Contact: Study Coordinator 28119836501
South Africa, Kwazulu-Natal
Enhancing Care Foundation-DICRS ( Site 1216)
[Recruiting]
Durban, Kwazulu-Natal, South Africa, 4091
Contact:Contact: Study Coordinator +27837471149
South Africa, Limpopo
Limpopo Clinical Research Initiative ( Site 1227)
[Recruiting]
Thabazimbi, Limpopo, South Africa, 0380
Contact:Contact: Study Coordinator +27834688998
South Africa, Western Cape
TREAD Research ( Site 1211)
[Recruiting]
Cape Town, Western Cape, South Africa, 7500
Contact:Contact: Study Coordinator +27219317825
Be Part Yoluntu Centre ( Site 1218)
[Recruiting]
Paarl, Western Cape, South Africa, 7626
Contact:Contact: Study Coordinator +27218683990
Clinical Projects Research Centre ( Site 1215)
[Recruiting]
Worcester, Western Cape, South Africa, 6850
Contact:Contact: Study Coordinator +27233474485
Spain
CAP Sardenya - Barcelona ( Site 1307)
[Recruiting]
Barcelona, Spain, 08025
Contact:Contact: Study Coordinator 34 93 567 43 84
Hospital Clinic ( Site 1304)
[Recruiting]
Barcelona, Spain, 08036
Contact:Contact: Study Coordinator 34 93 2275708
Hospital Universitari Germans Trias i Pujol ( Site 1303)
[Recruiting]
Barcelona, Spain, 08916
Contact:Contact: Study Coordinator +34934978849
Hospital Universitario Ramon y Cajal ( Site 1301)
[Recruiting]
Madrid, Spain, 28034
Contact:Contact: Study Coordinator +34913369100
Hospital Universitario La Paz ( Site 1300)
[Recruiting]
Madrid, Spain, 28046
Contact:Contact: Study Coordinator +34912077384
Spain, Madrid, Comunidad De
Hospital General Universitario Gregorio Maranon ( Site 1302)
[Recruiting]
Madrid, Madrid, Comunidad De, Spain, 28007
Contact:Contact: Study Coordinator +34637381956
Ukraine, Ivano-Frankivska Oblast
Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital ( Site 1605)
[Recruiting]
Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine, 76007
Contact:Contact: Study Coordinator +380342504906
CNE Central city clinical hospital of Ivano-Frankivsk city council ( Site 1604)
[Recruiting]
Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine, 76018
Contact:Contact: Study Coordinator +380504332119
MNE Ivano-Frankivsk Regional Phthisiology-Pulmonology Center ( Site 1603)
[Recruiting]
Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine, 76018
Contact:Contact: Study Coordinator +380679796690
Ukraine, Kharkivska Oblast
Non profit municipal enterprise City hospital student of Kharkiv city council ( Site 1621)
[Recruiting]
Kharkiv, Kharkivska Oblast, Ukraine, 61002
Contact:Contact: Study Coordinator +380505494926
Ukraine, Kyivska Oblast
LLC "Adonis plus" ( Site 1619)
[Recruiting]
Kyiv, Kyivska Oblast, Ukraine, 02002
Contact:Contact: Study Coordinator +380445170727
Kyiv railway clinical hospital 2 of Branch Health center ( Site 1602)
[Recruiting]
Kyiv, Kyivska Oblast, Ukraine, 03049
Contact:Contact: Study Coordinator +380667464061
ARTEM. State Holding Company ( Site 1618)
[Recruiting]
Kyiv, Kyivska Oblast, Ukraine, 04050
Contact:Contact: Study Coordinator +380444837430
United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust ( Site 1704)
[Recruiting]
Newcastle upon Tyne, United Kingdom, NE1 4LP
Contact:Contact: Study Coordinator 0191 233 6161
United Kingdom, Lancashire (England)
Layton Medical Centre ( Site 1705)
[Recruiting]
Blackpool, Lancashire (England), United Kingdom, FY3 7EN
Contact:Contact: Study Coordinator +441253951943
United Kingdom, London, City Of
Royal Free London NHS Foundation Trust ( Site 1700)
[Recruiting]
London, London, City Of, United Kingdom, NW3 2QG
Contact:Contact: Study Coordinator 442077940500362850
King's College Hospital ( Site 1707)
[Recruiting]
London, London, City Of, United Kingdom, SE5 9RS
Contact:Contact: Study Coordinator +442032994015
Open or close this module IPDSharing
Plan to Share IPD: Yes
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Supporting Information:
Time Frame:
Access Criteria:
URL: http://engagezone.msd.com/ds_documentation.php
Open or close this module References
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services